These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7031185)

  • 1. Speech disorders of Parkinsonism: a review.
    Critchley EM
    J Neurol Neurosurg Psychiatry; 1981 Sep; 44(9):751-8. PubMed ID: 7031185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Speech and voice disorders in Parkinson's disease].
    Martnez-Sánchez F
    Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arrest or acceleration of speech evoked by thalamic stimulation in the course of stereotaxic procedures for Parkinsonism.
    GUIOT G; HERTZOG E; RONDOT P; MOLINA P
    Brain; 1961 Sep; 84():363-79. PubMed ID: 13902875
    [No Abstract]   [Full Text] [Related]  

  • 4. Speech disturbances following stereotaxic surgery in ventrolateral thalamus.
    Petrovici JN
    Neurosurg Rev; 1980; 3(3):189-95. PubMed ID: 7022262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches.
    Dashtipour K; Tafreshi A; Lee J; Crawley B
    Neurodegener Dis Manag; 2018 Oct; 8(5):337-348. PubMed ID: 30223711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [F0 characteristics in Parkinsonian speech: Contrast between the effect of hypodopaminergy due to Parkinson's disease and that of the therapeutic delivery of L-Dopa].
    Ghio A; Robert D; Grigoli C; Mas M; Delooze C; Mercier C; Viallet F
    Rev Laryngol Otol Rhinol (Bord); 2014; 135(2):63-70. PubMed ID: 26521344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Language and speech correlates of anatomically verified lesions in thalamic surgery for parkinsonism.
    Samra K; Riklan M; Levita E; Zimmerman J; Waltz JM; Bergmann L; Cooper IS
    J Speech Hear Res; 1969 Sep; 12(3):510-40. PubMed ID: 4897811
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study.
    Tykalová T; Rusz J; Čmejla R; Klempíř J; Růžičková H; Roth J; Růžička E
    J Neural Transm (Vienna); 2015 Aug; 122(8):1135-42. PubMed ID: 25583417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
    Goberman AM; Coelho C
    NeuroRehabilitation; 2002; 17(3):237-46. PubMed ID: 12237505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of selegiline on speech performance in Parkinson's disease.
    Shea BR; Drummond SS; Metzer WS; Krueger KM
    Folia Phoniatr (Basel); 1993; 45(1):40-6. PubMed ID: 8482574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Parkinson's disease and levodopa on resting state functional connectivity related to speech prosody control.
    Elfmarková N; Gajdoš M; Mračková M; Mekyska J; Mikl M; Rektorová I
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S52-5. PubMed ID: 26363673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
    Rusz J; Tykalová T; Klempíř J; Čmejla R; Růžička E
    J Neural Transm (Vienna); 2016 Apr; 123(4):379-87. PubMed ID: 26843071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy.
    Rusz J; Tykalova T; Novotny M; Zogala D; Sonka K; Ruzicka E; Dusek P
    Neurology; 2021 Nov; 97(21):e2124-e2135. PubMed ID: 34607922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
    Pawlukowska W; Gołąb-Janowska M; Safranow K; Rotter I; Amernik K; Honczarenko K; Nowacki P
    Neurol Neurochir Pol; 2015; 49(5):302-6. PubMed ID: 26377981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emotional speech in Parkinson's disease.
    Möbes J; Joppich G; Stiebritz F; Dengler R; Schröder C
    Mov Disord; 2008 Apr; 23(6):824-9. PubMed ID: 18307245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the human thalamus in language and memory: evidence from electrophysiological studies.
    Johnson MD; Ojemann GA
    Brain Cogn; 2000 Mar; 42(2):218-30. PubMed ID: 10744921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up results of bilateral thalamotomy for parkinsonism.
    Matsumoto K; Asano T; Baba T; Miyamoto T; Ohmoto T
    Appl Neurophysiol; 1976-1977; 39(3-4):257-60. PubMed ID: 1052300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease.
    De Letter M; Van Borsel J; Boon P; De Bodt M; Dhooge I; Santens P
    Int J Speech Lang Pathol; 2010 Oct; 12(5):405-13. PubMed ID: 20602581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of memory and language function pre- and postthalamotomy with an attempt to define those patients at risk for postoperative dysfunction.
    Rossitch E; Zeidman SM; Nashold BS; Horner J; Walker J; Osborne D; Bullard DE
    Surg Neurol; 1988 Jan; 29(1):11-6. PubMed ID: 3276018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of speech therapy and pharmacological treatment in prosody of parkinsonians.
    Azevedo LL; Souza IS; Oliveira PM; Cardoso F
    Arq Neuropsiquiatr; 2015 Jan; 73(1):30-5. PubMed ID: 25608124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.